Organon experiences Schering's research 'religion'

The Star-Ledger sat down with Tom Koestler, the research chief for Schering-Plough, to review its progress developing new therapies and integrating the R&D section of Organon. Koestler and CEO Fred Hassan (photo) have been lauded for their work turning the company around. Analysts now generally give the company top marks for creating a promising pipeline. And while some have questioned the $14.4 billion price tag for Organon, there are five other late-stage products offering some major earnings potential. The combined R&D operations includes 7,000 employees working in 42 sites. It's all built around the working philosophy of "customer-focused product flow," where reps from research, manufacturing and marketing all have a hand in guiding the research. "That's kind of like a religion we follow at Schering-Plough," Koestler told the Star-Ledger. "You can't just rely on the scientists to develop a compound."

- check out the report from the Star-Ledger

ALSO: Schering-Plough says the FDA has accepted its NDA for asenapine, a tablet for schizophrenia and bipolar disorder. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.